Optically-integrated catheter for real-time monitoring of lesion formation during radiofrequency ablationTechnology #cu16008
Questions about this technology? Ask a Technology Manager
This technology employs an optically-integrated catheter to directly assess lesion formation in cardiac tissue during radiofrequency ablation (RFA) therapy.
Unmet Need: Real-time feedback on extent of tissue ablation during RFA treatment
Radiofrequency ablation (RFA) therapy treats cardiac irregularities by creating non-conducting lesions within the problematic heart tissue to disrupt aberrant electrical signals. However, current RFA treatments are unable to provide sufficient real-time feedback on the extent or sufficiency of tissue ablation, causing decreased long-term efficacy of treatment. Additional RFA treatments are often required to fully treat these irregularities and restore proper cardiac function.
The Technology: Optically-integrated catheter measures myoglobin content in real-time to track lesion formation during ablation
This technology is an optically-integrated catheter that is capable of directly assessing lesion formation during RFA therapy. This technology employs an RFA catheter that ablates cardiac tissue while concurrently measuring the concentrations of myoglobin-based proteins using diffuse reflectance spectroscopy. As these myoglobin-based proteins are known to accumulate in damaged or necrotic tissue, measuring their concentration during ablation enables real-time and continuous assessment of the extent and quality of lesion formation.
This technology has been used to characterize lesion ablation in ex-vivo human atrial tissue samples.
- Monitoring lesion formation during RFA treatment of cardiac arrhythmias and other cardiac conduction disorders
- Determining lesion formation in other ablation procedures, such as tumor ablation
- Measurement of myoglobin-based proteins during surgery
- Real-time characterization
- High spatial resolution
- Integrates into commercial RFA probes
- Direct method to determine lesion formation
- Reduces need for additional RFA treatments
Patent Pending (WO/2017/044941)
- Singh-Moon RP, Marboe CC, Hendon CP. “Near-infrared spectroscopy integrated catheter for characterization of myocardial tissues: preliminary demonstrations to radiofrequency ablation therapy for atrial fibrillation.” Biomedical Optics Express. 2015 June;6(7): 2494-2511.
Tech Ventures Reference:
Licensing Contact: Richard Nguyen